Competitor Analysis Toll-Like Receptor (TLR) Agonists & Antagonists
Product description
The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors (TLR) for treatment or prevention of cancer, infectious diseases, sepsis and allergy as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. TLRs have become attractive targets for activation or antagonism in pharmaceutical research. TLR agonists find use either alone or as adjuvants in combination with vaccine antigens. TLR antagonists are also under development for diseases with overwhelming immune response. Special attention has focused on the role of TLR agonists as novel adjuvants in prophylactic and therapeutic vaccines. They enhance dendritic cell function and their ability to prime T cells. Agonists that target toll-like receptors are being used clinically either alone or in combination with tumor antigens and showing initial success both in terms of enhancing immune responses and eliciting antitumor activity. TLR agonists and adjuvants are being investigated in a number of other therapeutic areas, such as in allergy, skin or infectious diseases.
The report includes a compilation of currently active projects in research and development of TLR agonists, antagonists, adjuvants and TLR-adjuvanted vaccines. In addition, the report lists company-specific R&D pipelines of TLR agonists and antagonists. Competitor projects are listed in a tabular format providing information on:
The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors (TLR) for treatment or prevention of cancer, infectious diseases, sepsis and allergy as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. TLRs have become attractive targets for activation or antagonism in pharmaceutical research. TLR agonists find use either alone or as adjuvants in combination with vaccine antigens. TLR antagonists are also under development for diseases with overwhelming immune response. Special attention has focused on the role of TLR agonists as novel adjuvants in prophylactic and therapeutic vaccines. They enhance dendritic cell function and their ability to prime T cells. Agonists that target toll-like receptors are being used clinically either alone or in combination with tumor antigens and showing initial success both in terms of enhancing immune responses and eliciting antitumor activity. TLR agonists and adjuvants are being investigated in a number of other therapeutic areas, such as in allergy, skin or infectious diseases.
The report includes a compilation of currently active projects in research and development of TLR agonists, antagonists, adjuvants and TLR-adjuvanted vaccines. In addition, the report lists company-specific R&D pipelines of TLR agonists and antagonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Therapeutic Area,
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
1. TLR AGONISTS – BY RECEPTOR SUBTYPE
TLR3 Agonists
TLR4 Agonists
TLR7 Agonists
TLR7/8 Agonists
TLR8 Agonists
TLR9 Agonists
2. TLR AGONISTS – BY THERAPEUTIC AREA
Dermatology
Gastrointestinal
Infectious & toxicology
Neurology & psychiatry
Oncology
Pulmonary & respiratory
Rheumatoid & autoimmune
3. TLR ANTAGONISTS – BY RECEPTOR SUBTYPE
TLR2 Antagonists
TLR4 Antagonists
TLR7/(8)/9 Antagonists
4. TLR ANTAGONISTS – BY THERAPEUTIC AREA
Cardiovascular & acute care
Gastrointestinal
Rheumatoid & autoimmune
5. TLR ADJUVANTS BY RECEPTOR SUBTYPE
TLR3 Adjuvants
TLR2/4 Adjuvants
TLR4 Adjuvants
TLR7/8/9 Adjuvants
TLR9 Adjuvants
TLR Adjuvants - unspecified
6. TLR – ADJUVANTED VACCINES – BY RECEPTOR SUBTYPE
Vaccines adjuvanted with TLR3 agonist
Vaccines adjuvanted with TLR4 agonist
Vaccines adjuvanted with TLR5 agonist
Vaccines adjuvanted with TLR9 agonist
Vaccines adjuvanted with unspecified TLR agonist
7. TLR – ADJUVANTED VACCINES – BY THERAPEUTIC AREA
Prophylactic TLR-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR3-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Pulmonary & Respiratory Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Oncology
Therapeutic TLR9-Adjuvanted Vaccines in Neurology & Psychiatry
Therapeutic unspecified TLR-Adjuvanted Vaccines in Oncology
CORPORATE TLR AGONIST & ANTAGONIST R&D PORTFOLIOS
TLR3 Agonists
TLR4 Agonists
TLR7 Agonists
TLR7/8 Agonists
TLR8 Agonists
TLR9 Agonists
2. TLR AGONISTS – BY THERAPEUTIC AREA
Dermatology
Gastrointestinal
Infectious & toxicology
Neurology & psychiatry
Oncology
Pulmonary & respiratory
Rheumatoid & autoimmune
3. TLR ANTAGONISTS – BY RECEPTOR SUBTYPE
TLR2 Antagonists
TLR4 Antagonists
TLR7/(8)/9 Antagonists
4. TLR ANTAGONISTS – BY THERAPEUTIC AREA
Cardiovascular & acute care
Gastrointestinal
Rheumatoid & autoimmune
5. TLR ADJUVANTS BY RECEPTOR SUBTYPE
TLR3 Adjuvants
TLR2/4 Adjuvants
TLR4 Adjuvants
TLR7/8/9 Adjuvants
TLR9 Adjuvants
TLR Adjuvants - unspecified
6. TLR – ADJUVANTED VACCINES – BY RECEPTOR SUBTYPE
Vaccines adjuvanted with TLR3 agonist
Vaccines adjuvanted with TLR4 agonist
Vaccines adjuvanted with TLR5 agonist
Vaccines adjuvanted with TLR9 agonist
Vaccines adjuvanted with unspecified TLR agonist
7. TLR – ADJUVANTED VACCINES – BY THERAPEUTIC AREA
Prophylactic TLR-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR3-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Oncology
Therapeutic TLR4-Adjuvanted Vaccines in Pulmonary & Respiratory Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Infectious Diseases
Therapeutic TLR9-Adjuvanted Vaccines in Oncology
Therapeutic TLR9-Adjuvanted Vaccines in Neurology & Psychiatry
Therapeutic unspecified TLR-Adjuvanted Vaccines in Oncology
CORPORATE TLR AGONIST & ANTAGONIST R&D PORTFOLIOS
ABOUT COMPETITOR ANALYSIS SERIES:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
